今日開啓招股,"港股生長髮育第一股"維昇藥業-B(2561.HK)獲創始股東Sofinnova三輪追投
今日,"港股生長髮育第一股"維昇藥業開始招股。公司擬全球發售990萬股,其中香港發售股份數目爲99萬股,國際發售股份數目爲891萬股;招股價爲68.44港元/股至75.28港元/股,招股時間爲3月13日上午九點至3月18日中午十二點,預計將於3月21日在港交所上市。
公司此次IPO招股引入5名基石投資者,包括安科生物、園豐、Vivo Capital、藥明生物、Reynold Lemkins。
據市場消息透露,除創始股東Vivo Capital基石追投外, Sofinnova在招股前期也已啓動完成第三輪追投。作爲歐洲老牌的生物科技投資機構,Sofinnova在歐洲生命科學領域擁有超過50年的行業經驗及卓越的投資記錄,對行業內優質候選藥物及企業價值有獨到眼光。
在過往全球醫藥投資中,Sofinnova憑藉敏銳洞察力,成功布局多個高潛力項目。市場分析認爲,創始股東連續三次追投維昇藥業,是基於對公司產品管線差異化優勢及商業潛力的高度認可。
看到管線,核心產品隆培促生長素是全球目前唯一一款經臨牀數據證實,療效優於生長激素日製劑的長效生長激素,目前已在中國提交上市申請,即將實現商業化。據悉,2024年隆培促生長素在歐美地區的銷售額高達2.02億歐元,摺合人民幣約15.36億元。維昇藥業的另外兩款創新藥物(那韋培肽和帕羅培特立帕肽),也均具備FIC/BIC潛力且處於全球領先地位,有望在未來中長期爲公司業績增長築牢根基。
相信隨着維昇藥業正式登陸港交所市場,其或有望吸引更多市場目光,在資本助力下加快產品商業化進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.